Mangkuanom Arwin Saleh, Satrio Revan, Mendel Brian, Firman Doni, Iryuza Nanda, Alkatiri Amir Aziz
Invasive Diagnostic and Non Surgical Intervention Division, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.
Front Cardiovasc Med. 2025 Jul 10;12:1607466. doi: 10.3389/fcvm.2025.1607466. eCollection 2025.
Contrast-induced nephropathy (CIN) is a risk in angiographic procedures, especially for patients with acute kidney injury (AKI). To mitigate this risk, ultra-low contrast percutaneous coronary intervention (ULC-PCI) has been developed, which minimizes the use of contrast agents.
A 54-year-old woman with a history of AKI from a prior percutaneous coronary intervention (PCI) was found to have coronary artery disease with three vessels disease and chronic total occlusion in the right coronary artery. To minimize contrast use, she underwent ultra-low contrast PCI using the "microcatheter injection" technique, with only 5 cc of contrast used during the procedure. At one-year follow-up, the patient's LVEF improved from 33% to 56%, symptoms resolved with no chest pain. Her estimated glomerular filtration rate (eGFR) showed no significant decrease, since serum creatinine increased slightly from 1.59 mg/dl to 1.61 mg/dl. and eGFR decreased from 39 to 38 ml/min/1.73 m in 72 h.
The microcatheter injection technique may serve as a viable strategy for percutaneous coronary intervention (PCI) in patients with eGFR < 30 ml/min/1.73 m or history of contrast-induced nephropathy.
造影剂肾病(CIN)是血管造影术的一种风险,尤其是对于急性肾损伤(AKI)患者。为降低这种风险,已开发出超低造影剂经皮冠状动脉介入治疗(ULC-PCI),其可将造影剂的使用降至最低。
一名54岁女性,既往经皮冠状动脉介入治疗(PCI)后有急性肾损伤病史,被发现患有冠状动脉疾病,三支血管病变,右冠状动脉慢性完全闭塞。为尽量减少造影剂使用,她采用“微导管注射”技术接受了超低造影剂PCI,手术过程中仅使用了5毫升造影剂。在一年的随访中,患者的左心室射血分数(LVEF)从33%提高到56%,症状缓解,无胸痛。她的估计肾小球滤过率(eGFR)没有显著下降,因为血清肌酐从1.59 mg/dl略有升至1.61 mg/dl,且eGFR在72小时内从39降至38 ml/min/1.73 m²。
对于估计肾小球滤过率(eGFR)<30 ml/min/1.73 m²或有造影剂肾病病史的患者,微导管注射技术可能是经皮冠状动脉介入治疗(PCI)的一种可行策略。